BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 27312194)

  • 21. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Level of Fecal Calprotectin Correlates With Severity of Small Bowel Crohn's Disease, Measured by Balloon-assisted Enteroscopy and Computed Tomography Enterography.
    Arai T; Takeuchi K; Miyamura M; Ishikawa R; Yamada A; Katsumata M; Igarashi Y; Suzuki Y
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):56-62. PubMed ID: 27565523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
    Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
    Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn's disease: a two-year prospective study.
    Ye L; Chen BQ; Wang SD; Shi H; Yang Z; Wang FY
    Scand J Gastroenterol; 2017 Oct; 52(10):1113-1119. PubMed ID: 28675068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Accuracy of Fecal Calprotectin for the Detection of Small Bowel Crohn's Disease through Capsule Endoscopy: An Updated Meta-Analysis and Systematic Review.
    Jung ES; Lee SP; Kae SH; Kim JH; Kim HS; Jang HJ
    Gut Liver; 2021 Sep; 15(5):732-741. PubMed ID: 33361549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of disease location on fecal calprotectin levels in Crohn's disease.
    Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
    Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
    Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H
    Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging.
    Faubion WA; Fletcher JG; O'Byrne S; Feagan BG; de Villiers WJ; Salzberg B; Plevy S; Proctor DD; Valentine JF; Higgins PD; Harris JM; Diehl L; Wright L; Tew GW; Luca D; Basu K; Keir ME
    Am J Gastroenterol; 2013 Dec; 108(12):1891-900. PubMed ID: 24126633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
    Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
    Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crohn's disease: small bowel motility impairment correlates with inflammatory-related markers C-reactive protein and calprotectin.
    Bickelhaupt S; Pazahr S; Chuck N; Blume I; Froehlich JM; Cattin R; Raible S; Bouquet H; Bill U; Rogler G; Frei P; Boss A; Patak MA
    Neurogastroenterol Motil; 2013 Jun; 25(6):467-73. PubMed ID: 23495824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
    Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound.
    Orlando A; Modesto I; Castiglione F; Scala L; Scimeca D; Rispo A; Teresi S; Mocciaro F; Criscuoli V; Marrone C; Platania P; De Falco T; Maisano S; Nicoli N; Cottone M
    Eur Rev Med Pharmacol Sci; 2006; 10(1):17-22. PubMed ID: 16494106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffusion-weighted imaging in quiescent Crohn's disease: correlation with inflammatory biomarkers and video capsule endoscopy.
    Klang E; Kopylov U; Eliakim R; Rozendorn N; Yablecovitch D; Lahat A; Ben-Horin S; Amitai MM
    Clin Radiol; 2017 Sep; 72(9):798.e7-798.e13. PubMed ID: 28506799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
    Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
    Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn's disease.
    Eder P; Stawczyk-Eder K; Łykowska-Szuber L; Krela-Kaźmierczak I; Klimczak K; Szymczak A; Szachta P; Linke K
    Pol Arch Med Wewn; 2014; 124(1-2):51-7. PubMed ID: 24424551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
    Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn's disease: A European multicentre observational cohort study.
    Tai FWD; Ellul P; Elosua A; Fernandez-Urien I; Tontini GE; Elli L; Eliakim R; Kopylov U; Koo S; Parker C; Panter S; Sidhu R; McAlindon M
    United European Gastroenterol J; 2021 Mar; 9(2):248-255. PubMed ID: 32741315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Faecal lactoferrin, capsule endoscopy and Crohn's disease. Is there a three way relationship? A pilot study.
    Sidhu R; Sanders DS; Wilson P; Foye L; Morley S; McAlindon ME
    J Gastrointestin Liver Dis; 2010 Sep; 19(3):257-60. PubMed ID: 20922188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.